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ABSTRACT 
 
Hepatocellular adenomas (HCAs) have recently identified as a heterogeneous group, differing based 
on genotypic as well as morphologic characteristics.  HCAs are most frequently found in females on 
oral contraception. A type of HCA, inflammatory HCA is also known as telangiectatic HCA and 
previously referred to as telangiectatic focal nodular hyperplasia. We present the first case of HCA 
arising from the liver with primary sclerosing cholangitis (PSC). This case is a 30’-year-old man with 
a past medical history of PSC, ulcerative colitis, and diabetes mellitus. A routine ultrasonography for 
PSC detected the gradually enlarged intrahepatic mass. Liver biopsy could reveal the diagnosis of 
telangiectatic/inflammatory HCA by morphological and immunohistochemical analyses. Partial 
hepatectomy was performed and the resected liver was pathologically diagnosed as the 
telangiectatic/inflammatory HCA arising in PSC. This is the first case report of such an association 
and here we review the current developments and literature of this rare tumor and the association with 
an activated inflammatory related tumorgenetic pathway and PSC. 
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INTRODUCTION 
 
With recent molecular advances profiling and subclassifying hepatocellular adenomas 
(HCAs), the entity of telangiectatic hepatocellular adenoma, previously thought to be a subtype of 
focal nodular hyperplasia (FNH), has now been reclassified as a variant of the inflammatory HCA 
subtype.1-4 Telangiectatic/inflammatory HCA is a rare benign tumor characterized as a well-
demarcated, unencapsulated tumor with partial lobulation, portal tract-like structures with dystrophic 
or thickened arteries surrounded by an inflammatory infiltrate and/or ductular reaction, and scattered 
areas of peliosis and sinusoidal dilation.1, 5, 6 The diagnosis is based on these key morphologic features 
and can be further supported with immunohistochemistry and molecular genotyping.1-7 
HCAs are most frequently and classically found in females on oral contraception.8 
Additionally, telangiectatic/inflammatory HCA have specifically been linked to an increased body 
mass index and a generalized systemic inflammatory condition.6 Other rare, but well-documented, 
associations with HCAs include: glycogensosis,4, 9 familial adenomatous polyposis coli,4, 10, 11 Danazol 
treatment,4, 12, 13 portal canal shunt,4 Cushing syndrome,4 and diabetes mellitus with liver 
adenomatosis.14 Here we report the first case of a telangiectatic/inflammatory HCA occurring in a 




Clinical course: This case is a 30’-year-old man at diagnosis of HCA. The patient first 
presented with acute hepatitis at the age of 11 and was then diagnosed with PSC at the age of 16. 
When he was 15 years old he presented with hematochezia and diarrhea and was then diagnosed with 
ulcerative colitis (UC).  He was also diagnosed with diabetes mellitus (DM) type 2, and at age 28 he 
was noted to have cholelithiasis.  Since then, his UC has been in remission and his DM has been well-
controlled with medication. He has no history of steroid use and is a social drinker. 
He initially presented with a low echo lesion in the left lobe found during a routine PSC 
ultrasonography screening. The lesion was followed and gradually enlarged in size. Two years later, 
the lesion was biopsied and then the patient underwent a partial hepatectomy of the left lobe. On 
physical examination on admission, he has a body mass index (BMI) of 31 (92kg and 172cm), and a 
blood pressure of 106/76mmHg. Laboratory data are as follows (underline denotes abnormal data) : 
WBC 5200/ml, RBC 476 x 104 /ml, PLT 26.8 x 104 /ml, ESR 24 mm/h, C-reactive protein (CRP) 0.5 
mg/dl, TP 7.4 g/dl, Alb 3.9 g/dl, T-Bil 0.8 mg/dl, ALP 706 IU/l, ChE 5051 IU/l, AST 43 IU/l, ALT 91 
IU/l, LDH 178 IU/l, γ-GTP 718 IU/l, AMY 31 IU/l, ZTT 19.2 U, LDL-C 166 mg/dl, TG 182 mg/dl, 
HDL-C 52 mg/dl, UN 10 mg/dl, S-Cr 0.56 mg/dl, Na 138 mEq/l , K 4.3 mEq/l, Cl 101 mEq/l , Ca 9.3 
mg/dl, UA 4.7 mg/dl, HbA1c 7.0 %, IgG 1688 mg/dl, IgA 267 mg/dl, IgM 147 mg/dl, ANA (- , < 40), 
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AMA(-, < 20), M2Ab(-, < 5), SSA(-, <5), SSB (-, <5) , C-ANCA 222 U/l, HBs-Ag (-), HCV-Ab(-), 
AFP 3.4ng/ml, and PIVKA-II 39 mAU/ml.  
Imaging: The initial screening ultrasonography revealed a low echo lesion in the left lobe and 
the surrounding liver showed fatty change. CT scans were then performed to further evaluate the 
hepatic mass. An unenhanced CT scan showed irregular fatty change. On a dynamic contrast CT scan, 
the mass revealed enhancement in the hepatic arterial phase and persistent enhancement in the portal-
venous and equilibrium phase (Fig.1). No other masses were found in the liver.  After 10 months 
of  follow up, ultrasonography and CT scan showed enlargement of the mass. On MRI imaging 
the mass showed high intensity on both T1 and T2 weighted images. The T2-weighted fat 
suppressed image and the out of phase image also showed high intensity, which indicated that 
there was no fat component within the lesion. The SPIO-enhanced MRI showed iso-intensity 
compared to the surrounding liver, and the Gd-EOB-MRI showed strong enhancement on the 
arterial phase and iso-intensity in comparison with the surrounding liver on portal-venous and 
equilibrium phase. On the hepatobiliary phase, the lesion showed hypo-intensity (Fig.1), but it 
seemed to have a slight uptake of Gd-EOB-DTPA. From these images, tumor capsule was unclear. 
Overall, these findings suggest the hypervascular lesion showing a gradually enlargement. 
Especially, as differential diagnoses, focal nodular hyperplasia, angiomyolipoma, HCA, and 
hepatocellular carcinoma were considered. As for the background liver, MRCP and ERCP showed 
multifocal intrahepatic bile duct strictures suggesting PSC. 
Histology of liver needle biopsy (Fig.2): Specimen contained tumorous and background 
areas. Tumorous lesion composed of uniform population of pale eosinophilic tumor cells resembling 
hepatocytes. Many of the tumor cells had glycogenated nuclei and no nuclear atypia was seen. 
Pericellular frame of reticulin fiber was well-preserved. A few portal tract-like structures lacking bile 
ducts were found in this lesion and around them mild lymphocytic infiltration and copper-binding 
proteins positive for Orcein staining were scattered.  
Pathology of partially resected liver (Fig.3): Gross examination of the liver excision 
specimen revealed a non-encapsulated, well-circumscribed 2.6 cm soft tan nodule.  The center of the 
nodule had several small foci of hemorrhage but no central scar or areas of fibrosis were identified.  
Histology revealed a well-demarcated nodule composed of uniform hepatocyte-like cells without 
cellular atypia. Within the tumor mass there were abundant portal tract-like structures, each containing 
two to three arteries. The arteries varied in size and caliber, some thickened, dystrophic and/or ectatic. 
Surrounding these portal tract-like structures was a brisk lymphoplasmacytic infiltrate with rare foci of 
an associated ductular proliferation. Areas of macrovesicular steatosis were identified within the 
tumor, predominately surrounding the portal tract-like structures.  Peliosis and areas with sinusoidal 
dilation and congestion were also present. The background liver showed findings consisted with early 
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stage of primary sclerosing cholangitis with a lymphoplasmacytic portal tract infiltrate centered on the 
bile ducts with bile duct damage and some areas of concentric fibrosis surrounding bile ducts (onion-
skin like lesion).  
Immunohistochemistry: Immunohistochemistry using needle and surgically resected liver 
specimens demonstrated that the tumor cells stained positive for serum amyloid A (SAA, granular 
cytoplasmic staining pattern) and strongly positive for CRP (Fig.3) and had no nuclear staining for β-
catenin. CD34 highlighted the arteries within the portal tract-like structures and also showed a 
sinusoidal inflow staining pattern (Fig.3). Cytokeratins 7 and 19 highlighted a mild ductular 
proliferation surrounding rare portal tract-like structures and also bile ducts and a ductular reaction 
within the background liver. Overall, these histopathologic and immunohistochemical findings were 




Recent molecular studies have shown that HCAs are composed of a heterogeneous group of 
tumors, differing based on hepatocyte nuclear factor (HNF)-1α mutations, β-catenin activation, and 
morphologic phenotypes.1-7, 15 Although several nomenclatures of HCA subclassification, according to 
new WHO classification edited in 2010, HCAs can now be subclassified into four categories, 1) 
HNF1α-inactivated HCA (tumors with HNF1α mutation with steatosis, lack of cytologic 
abnormalities, no inflammatory infiltrate, and negative liver fatty acid protein expression), 2) β-
catenin-activated HCA (tumors with β-catenin mutation with frequent cytologic abnormalities and 
pseudo-glandular formation), 3) Inflammatory HCA (telangiectatic/inflammatory HCA without 
HNF1α or β-catenin activation with cytological abnormalities, ductular reaction, inflammatory 
infiltrates, and frequent gp130 mutation), 4) Unclassified HCA (tumors without any 
mutation/activation and no inflammatory infiltrate).1-4, 15, 16 This morphologic and genotypic 
classification is important for  prognostic and diagnostic purposes, since those tumors with β-catenin 
activation have been shown to have an increased risk to progress to hepatocellular carcinoma.2, 17, 18 
Furthermore, these studies have also clarified the status of telangiectatic HCA, previously referred to 
as telangiectatic focal nodular hyperplasia.19 Telangiectatic HCAs are not only monoclonal tumors,1, 5 
but also share many features of inflammatory HCA, both morphologically and genotypically.1-7 Both 
telangiectatic and inflammatory HCAs fit into the third group of HCAs (telangiectatic/inflammatory 
HCA), with the lack of HNF1α mutation or β-catenin activation and with an inflammatory infiltrate 
surrounding portal tract like-structures. A risk of malignant transformation in 
telangiectatic/inflammatory HCA without β-catenin mutation might be rather low.16 Moreover, 
Dokmak et al,20 reported  that patients with HCAs greater than 5 cm, telangiectatic or unclassified 
subtypes, and men have an increased risk of complication of hepatic resection. The present male case 
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was unlikely malignant transformation and the risk of complication of resection was also feared. 
However, the mass of this patent was progressively enlarged from 2.0cm to 2.8cm over the course of 
10 months and the potential malignant transformation entirely could not be denied. Therefore, this 
patient desired a surgical treatment as a treatment choice. 
While all types of HAs are classically found in females and are strongly associated with the 
use of oral contraception,8 the telangiectatic/inflammatory HCA subtypes have been specifically 
linked to obesity, alcohol, and most importantly to an inflammatory syndrome. Moreover, patients 
with telangiectatic/inflammatory HCA have been shown to have increased blood levels of CRP and 
fibrinogen and following surgical removal of the tumors, these patients subsequently have reduced 
blood level of these inflammatory makers.6 In the present case of telangiectatic/inflammatory HCA, 
however, the level of serum CRP was not increased. Because CRP level is affected by the size of 
tumor, as a possible reason, the tumor size of this patient is still small, compared with that of typical 
HCA. Also telangiectatic/inflammatory HCA characteristically have an immunohistochemical pattern 
of SAA and CRP overexpression and these markers are overexpressed only within the tumor 
hepatocytes.3 Moreover, the investigation of MRI findings for each type of HCAs has already 
reported.15  Telangiectatic/inflammatory HCA subtype is characterized by the high intensity signal on 
T2-weighted sequences and our present case also shows the similar MRI findings. Finally, direct 
evidence for an aberrant activation of an inflammatory pathway in these tumors has been shown with 
the identification of interleukin (IL)-6ST mutations, encoding gp130 receptor, occurring in 60% of 
telangiectatic/inflammatory HCAs.21 This mutation leads to an activation of the IL-6/STAT-3 
signaling pathway, which provides a mechanism for the inflammatory infiltrate found within the 
tumors, the increased levels of circulating inflammatory markers in these patients, and may serve as a 
critical link to an inflammatory related tumorgenetic pathway.22  
PSC is a well-known chronic inflammatory condition targeting the intrahepatic and 
extrahepatic large bile ducts, leading to fibrotic strictures and eventually biliary cirrhosis. The risk for 
cholangiocarcinoma is up to 13%,23 and hepatocellular carcinoma is a rare complication.24  In this case 
report, the patient had a long-standing history of PSC and ulcerative colitis. No other reports have 
associated HCA with PSC. A literature search only revealed one cases report of a patient with PSC 
and FNH.24 Furthermore this is the first report of a telangiectatic/inflammatory HCA associated with a 
specific underlying chronic inflammatory condition. This case is important in that it identifies PSC as 
a possible associated risk factor for the development of telangiectatic/inflammatory HCA. The 
pathogenesis for the development of cholangiocarcinoma arising in patients with PSC and other 
chronic inflammatory disorders of the bile ducts has been linked to an activation of the IL-6 and 
STAT3 pathway.25-29 This common inflammatory pathway of IL-6/STAT3 has also been well-
documented in colitis associated colon cancer in patients with inflammatory bowel disease.22 Given 
that telangiectatic/inflammatory HCA also are found to have an activated IL-6/STAT3 signaling 
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pathway, perhaps this patient’s underlying chronic inflammatory diseases of PSC and/or UC, may 
have predisposed him to the development of a telangiectatic/inflammatory HCA.   
In summary, here we report the first case of a telangiectatic/inflammatory HCA associated 
with PSC. Further studies are necessary to identify a possibly link or associated inflammatory 
mechanism between PSC and telangiectatic/inflammatory HCA. 
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FIGURE and LEGENEDS 
 
 





Fig.1  Dynamic contrast CT scan (initial CT; A, follow-up CT; B) and Gd-EOB-MRI (C). On a 
dynamic contrast CT scan, the mass (arrows) revealed enhancement in the hepatic arterial phase. 
This mass became enlarged from 2.0cm (A, in April 2008) to 2.8cm (B, in February 2009). No 
other masses were found in the liver. On the hepatobiliary phase of the Gd-EOB-MRI, the mass 
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Fig.3  Surgically resected liver. A: A non-encapsulated, well-circumscribed 2.6 cm soft tan nodule 
was found in the hepatic subcapsular area. Bar indicates 1cm.  B: Nodule was well-demarcated 
and portal tracts-like structures were found within the nodule. Arrowheads denote a border of 
nodule. C: Around portal tract-like structures containing several muscular arteries (arrows), 
brisk lymphoplasmacytic infiltration and macrovesicular steatosis were scattered. D: 
Immunohistochemistry for C-reactive protein (CRP). Strong positivity was found in nodule. E: 
Immunohistochemistry for serum amyloid A (SAA). Granular cytoplasmic staining was found.  
F: Immunohistochemistry for CD34 highlighted the arteries (arrow) within the portal tract-like 
structures and also showed a sinusoidal inflow staining pattern (arrowheads).  G: Background 
liver. In portal tracts, mild to moderate lymphoplasmacytic infiltration and concentric fibrosis 
surrounding bile ducts (onion-skin like lesion, arrow) indicating primary sclerosing cholangitis 
were found. 
 
 
 
